Srikripa Devarakonda
Stock Analyst at Truist Securities
(1.88)
# 3,052
Out of 4,869 analysts
63
Total ratings
32.2%
Success rate
-5.96%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Srikripa Devarakonda
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INCY Incyte | Maintains: Hold | $72 → $73 | $68.46 | +6.63% | 10 | May 27, 2025 | |
| ARVN Arvinas | Downgrades: Hold | $21 → $11 | $7.44 | +47.85% | 1 | May 5, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $975 → $940 | $509.72 | +84.41% | 7 | Apr 30, 2025 | |
| BIIB Biogen | Maintains: Buy | $210 → $199 | $127.04 | +56.64% | 4 | Apr 29, 2025 | |
| KROS Keros Therapeutics | Maintains: Buy | $43 → $25 | $13.49 | +85.32% | 5 | Apr 9, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $60 → $76 | $53.34 | +42.48% | 2 | Mar 11, 2025 | |
| LLY Eli Lilly and Company | Maintains: Buy | $1,029 → $1,038 | $762.73 | +36.09% | 4 | Feb 3, 2025 | |
| ABBV AbbVie | Maintains: Buy | $211 → $217 | $185.30 | +17.11% | 3 | Feb 3, 2025 | |
| PFE Pfizer | Maintains: Buy | $36 → $32 | $23.97 | +33.50% | 1 | Dec 18, 2024 | |
| EWTX Edgewise Therapeutics | Maintains: Buy | $33 → $50 | $14.29 | +249.90% | 6 | Nov 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $45 | $34.04 | +32.20% | 4 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $54 → $53 | $45.87 | +15.54% | 3 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $54 | $1.81 | +2,883.43% | 1 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $15 | $4.93 | +204.26% | 7 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $11.48 | +213.59% | 1 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $86 → $70 | $32.43 | +115.85% | 4 | May 29, 2024 |
Incyte
May 27, 2025
Maintains: Hold
Price Target: $72 → $73
Current: $68.46
Upside: +6.63%
Arvinas
May 5, 2025
Downgrades: Hold
Price Target: $21 → $11
Current: $7.44
Upside: +47.85%
Regeneron Pharmaceuticals
Apr 30, 2025
Maintains: Buy
Price Target: $975 → $940
Current: $509.72
Upside: +84.41%
Biogen
Apr 29, 2025
Maintains: Buy
Price Target: $210 → $199
Current: $127.04
Upside: +56.64%
Keros Therapeutics
Apr 9, 2025
Maintains: Buy
Price Target: $43 → $25
Current: $13.49
Upside: +85.32%
Protagonist Therapeutics
Mar 11, 2025
Maintains: Buy
Price Target: $60 → $76
Current: $53.34
Upside: +42.48%
Eli Lilly and Company
Feb 3, 2025
Maintains: Buy
Price Target: $1,029 → $1,038
Current: $762.73
Upside: +36.09%
AbbVie
Feb 3, 2025
Maintains: Buy
Price Target: $211 → $217
Current: $185.30
Upside: +17.11%
Pfizer
Dec 18, 2024
Maintains: Buy
Price Target: $36 → $32
Current: $23.97
Upside: +33.50%
Edgewise Therapeutics
Nov 27, 2024
Maintains: Buy
Price Target: $33 → $50
Current: $14.29
Upside: +249.90%
Nov 25, 2024
Maintains: Buy
Price Target: $36 → $45
Current: $34.04
Upside: +32.20%
Nov 1, 2024
Reiterates: Buy
Price Target: $54 → $53
Current: $45.87
Upside: +15.54%
Sep 27, 2024
Upgrades: Buy
Price Target: $54
Current: $1.81
Upside: +2,883.43%
Aug 13, 2024
Maintains: Buy
Price Target: $18 → $15
Current: $4.93
Upside: +204.26%
Jul 31, 2024
Initiates: Buy
Price Target: $36
Current: $11.48
Upside: +213.59%
May 29, 2024
Maintains: Buy
Price Target: $86 → $70
Current: $32.43
Upside: +115.85%